logo-loader
viewAnteris Technologies Ltd

Anteris Technologies begins early transcatheter aortic valve replacement animal study

The study will allow the company to make refinements to the DurAVR™ aortic valve, which will be applied to the device used in the planned US FDA submission for a human clinical trial in 2021.

Anteris Technologies Ltd - Anteris Technologies commences transcatheter aortic valve replacement (TAVR) animal study
The study will be completed by December 31 2020

Anteris Technologies Ltd (ASX:AVR) has implanted its proprietary DurAVR™ Transcatheter Heart Valve into the first three animals as part of a transcatheter aortic valve replacement (TAVR) study.

The first feasibility study in pigs aims to confirm DurAVR™ valve deployment and fixation (anchoring) as well as providing insight into the valve’s haemodynamic function.

Anteris chief executive officer and managing director Wayne Paterson said: “The DurAVR™ valve continues to deliver superior performance observed to date.

“This preclinical study provides encouraging data and, importantly, will inform our development program and product design fine-tuning.”

The study of nine animals is being conducted in Minneapolis, USA, and is scheduled to be completed by December 31, 2020.

Value function measured

The three pigs were implanted with a 25-millimetre valve via a catheter by a trans-apical approach.

The Effective Orifice Areas (EOA) were 2.45 centimetres squared on initial readings, consistent with the positive results observed in patients surgically implanted in the first-in-human SAVR clinical study and in previous animal and laboratory studies of the DurAVR™ valve.

The EOA, a measurement of haemodynamic function, is a significant indicator of valve function and performance.

Significance of the study

The study replicated the findings of the 3D single-piece DurAVR™ aortic valve as shown in the surgical aortic valve replacement (SAVR) animal study and, thus far, in the first-in-human SAVR clinical study of the DurAVR™ valve underway at the University Hospitals, Leuven in Belgium.

This early feasibility study is critical as the company moves toward the next phase of development.

The lessons learned in this study will allow Anteris to make refinements to the frame and delivery system for the DurAVR™ aortic valve, which ultimately will be applied to the device used in the planned US FDA submission for a human clinical trial in 2021.

Quick facts: Anteris Technologies Ltd

Price: 3.3 AUD

ASX:AVR
Market: ASX
Market Cap: $19.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Anteris Technologies 'delivering on its goals despite pandemic'

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are...

on 6/7/20

2 min read